DNTH vs RCUS vs JPM vs IMVT vs MRK

For growth investors, JPMorgan Chase & Co.

(JPM) is the stronger pick with 3. 3% revenue growth year-over-year, versus -67. 3% for Dianthus Therapeutics, Inc. (DNTH). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Dianthus Therapeutics, Inc. (DNTH) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 15. 6x versus Merck & Co. , Inc. at 16. 6x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 1. 08x versus Merck & Co. , Inc. 's 1. 11x — a reasonable growth-adjusted valuation.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +207. 0%, compared to -58. 7% for Dianthus Therapeutics, Inc. (DNTH). Over 10 years, the gap is even starker: JPM returned +454. 4% versus DNTH's -67. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 34β versus Arcus Biosciences, Inc. 's 1. 98β — meaning RCUS is approximately 480% more volatile than MRK relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), JPMorgan Chase & Co.

(JPM) is pulling ahead at 3. 3% versus -67. 3% for Dianthus Therapeutics, Inc. (DNTH). On earnings-per-share growth, the picture is similar: Merck & Co. , Inc. grew EPS 8. 0% year-over-year, compared to -64. 7% for Dianthus Therapeutics, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -79. 7% for Dianthus Therapeutics, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -87. 4% for DNTH. At the gross margin level — before operating expenses — DNTH leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 1. 08x versus Merck & Co. , Inc. 's 1. 11x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 1x forward P/E versus 23. 5x for Merck & Co. , Inc. — 9. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DNTH: 46. 4% to $111. 91.

In this comparison, MRK (2.

7% yield), JPM (1. 9% yield) pay a dividend. DNTH, RCUS, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 2. 7% yield, +172. 8% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRK: +172. 8%, RCUS: +37. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (DNTH (Healthcare) and RCUS (Healthcare) and JPM (Financial Services) and IMVT (Healthcare) and MRK (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DNTH is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; IMVT is a small-cap quality compounder stock; MRK is a large-cap deep-value stock. JPM, MRK pay a dividend while DNTH, RCUS, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.